Bates D, Cartlidge N E, French J M, Jackson M J, Nightingale S, Shaw D A, Smith S, Woo E, Hawkins S A, Millar J H
Department of Neurology, University of Newcastle upon Tyne, UK.
J Neurol Neurosurg Psychiatry. 1989 Jan;52(1):18-22. doi: 10.1136/jnnp.52.1.18.
A trial of n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis has been conducted over a 5 year period. Ambulant patients (312) with acute remitting disease were randomly allocated to treatment or placebo. Both groups were given dietary advice to increase the intake of n-6 polyunsaturated fatty acids and the treatment group in addition received capsules containing n-3 polyunsaturated fatty acids. Analysis of clinical outcome at the end of 2 years of treatment was made in terms of the duration, frequency and severity of relapses and the number of patients who had improved or remained unchanged. The results showed no significant difference at the usual 95% confidence limits but there was a trend in favour of the group treated with n-3 polyunsaturated fatty acids in all parameters examined.
一项关于n-3多不饱和脂肪酸治疗多发性硬化症的试验进行了5年。312名急性缓解期的门诊患者被随机分配接受治疗或安慰剂。两组都接受了增加n-6多不饱和脂肪酸摄入量的饮食建议，治疗组还额外服用了含有n-3多不饱和脂肪酸的胶囊。根据复发的持续时间、频率和严重程度以及病情改善或未改变的患者数量，对治疗2年后的临床结果进行了分析。结果显示，在通常的95%置信区间内没有显著差异，但在所有检查参数中，有一个有利于n-3多不饱和脂肪酸治疗组的趋势。
